New report signals slowdown in the fight against malaria

Reference :



17 December 2012  | MONROVIA, Liberia/GENEVA –During the past decade, a concerted effort by endemic countries, donors and global malaria partners led to strengthened malaria control around the world. The scale-up of malaria prevention and control interventions had the greatest impact in countries with high malaria transmission; 58% of the 1.1 million lives saved during this period were in the ten highest burden countries.

However, after a rapid expansion between 2004 and 2009, global funding for malaria prevention and control levelled off between 2010 and 2012, and progress in the delivery of some life-saving commodities has slowed. According to the World malaria report 2012, these developments are signs of a slowdown that could threaten to reverse the remarkable recent gains in the fight against one of the world’s leading infectious killers.

For example, the number of long-lasting insecticidal nets (LLINs) delivered to endemic countries in sub-Saharan Africa dropped from a peak of 145 million in 2010 to an estimated 66 million in 2012. This means that many households will be unable to replace existing bed nets when required, exposing more people to the potentially deadly disease.

The expansion of indoor residual spraying programmes also levelled off, with coverage levels in the WHO African Region staying at 11% of the population at risk (77 million people) between 2010 and 2011.

“During the past eight years, scaled-up malaria control helped us avert over a million deaths. We must maintain this momentum and do our utmost to prevent resurgences,” says Ellen Johnson Sirleaf, President of Liberia and Chair of the African Leaders Malaria Alliance, who held an official launch event for the report in Monrovia, Liberia.

Tracking progress towards 2015 targets

According to the report, 50 countries around the world are on track to reduce their malaria case incidence rates by 75% by 2015 – in line with World Health Assembly and Roll Back Malaria targets. However, these 50 countries only represent 3%, or 7 million, of the malaria cases that were estimated to have occurred in 2000, the benchmark against which progress is measured.

“Global targets for reducing the malaria burden will not be reached unless progress is accelerated in the highest burden countries,” says Dr Robert Newman, Director of the WHO Global Malaria Programme in Geneva. “These countries are in a precarious situation and most of them need urgent financial assistance to procure and distribute life-saving commodities.”

The malaria burden is concentrated in 14 endemic countries, which account for an estimated 80% of malaria deaths. The Democratic Republic of the Congo and Nigeria are the most affected countries in sub-Saharan Africa, while India is the most affected country in South-East Asia.

“The multi-pronged strategy to fight malaria, outlined in the Global Malaria Action Plan, is working. However, in order to prevent a resurgence of malaria in some countries, we urgently need fresh ideas on new financing mechanisms that will reap greater resources for malaria,” says Dr Fatoumata Nafo-Traoré, Executive Director of the Roll Back Malaria Partnership. “We are exploring many options – financial transaction taxes, airline ticket taxes together with UNITAID, and a “malaria bond”, among others.”

Major funding gap

The World malaria report 2012 indicates that international funding for malaria appears to have reached a plateau well below the level required to reach the health-related Millennium Development Goals and other internationally-agreed global malaria targets.

An estimated US$ 5.1 billion is needed every year between 2011 and 2020 to achieve universal access to malaria interventions in the 99 countries with on-going malaria transmission. While many countries have increased domestic financing for malaria control, the total available global funding remained at 2.3 billion in 2011 – less than half of what is needed.

This means that millions of people living in highly endemic areas continue to lack access to effective malaria prevention, diagnostic testing, and treatment. Efforts to prevent the emergence and spread of parasite resistance to antimalarial medicines and mosquito resistance to insecticides are also constrained by inadequate funding.

While the plateauing of funding is affecting the scale-up of some interventions, the report documents a major increase in the sales of rapid diagnostics tests (RDTs), from 88 million in 2010 to 155 million in 2011, as well as a substantial improvement in the quality of tests over recent years. Deliveries to countries of artemisinin-based combination therapies, or ACTs, the treatment recommended by the WHO for the treatment of falciparum malaria, also increased substantially, from 181 million in 2010 to 278 million in 2011, largely as a result of increased sales of subsidized ACTs in the private sector.

Weak surveillance systems

Tracking progress is a major challenge in malaria control. At present, malaria surveillance systems detect only one-tenth of the estimated global number of cases. In as many as 41 countries around the world, it is not possible to make a reliable assessment of malaria trends due to incompleteness or inconsistency of reporting over time.

Stronger malaria surveillance systems are urgently needed to enable a timely and effective malaria response in endemic regions, to prevent outbreaks and resurgences and to ensure that interventions are delivered to areas where they are most needed. In April 2012, WHO launched new malaria surveillance manuals, as part of its T3: Test. Treat. Track. initiative.

Notes for editors:

The World malaria report 2012 summarizes information received from 99 countries with on-going transmission and other sources, and updates the analyses presented in the 2011 report.

Malaria is an entirely preventable and treatable vector-borne disease. In 2010, an estimated 219 million cases occurred globally, while the disease killed about 660 000 people, mostly children under five years of age.

For more information please contact:

Glenn Thomas
WHO Communications
Telephone: +41 22 791 3983
Mobile: +41 79 509 0677

[Vacancy]:UCSI University, Kuala Lumpur

Reference :


Location :Cheras, Kuala Lumpur (Malaysia)
  • To contribute in educating the next generation of
    professional pharmacists/doctors
  • Discovery and development for betterment of
  • To counsel students pertaining to their career &
    academic achievements & goals.
  • To contribute in research and development projects,
    materials and curriculum/syllabi development for teaching purposes.
  • To perform other academic related duties
Area of Specialisation:
  • Clinical Pharmacy
  • Candidates with relevant PhD qualification or Master
  • Minimum of 2-3 years experience in related field.
  • Relevant undergraduate degree is required.

Attractive remuneration schemes and
fringe benefits await suitable candidates. Applicants should submit their résumé
stating comprehensive details of experience and qualifications, current and
expected salary, a recent passport-size photo (n.r.) and contact telephone
number to the address below to :-

Head of Recruitment
Human Resource Office
UCSI University
No. 1, Jalan Menara Gading
56000 Kuala Lumpur

Tel: 03-91018880


All applicants will
be treated with strict confidence.

Only shortlisted candidates will be

[Vacancy] : Retial Pharmacists Needed-Klang/Port Klang

Reference :


We invite two pharmacists to join our established community
pharmacy practice in Klang/Port Klang.  Remuneration package includes a monthly
performance incentive. Please email for details


Pharmacist Annual Retention 2013-Submission by MPS Closed. Please submit direct to Lembaga Farmasi

Reference :


you intend to apply on your own the Pharmacist Annual
Retention, please ensure you follow the steps below:-
MPS offer to assist pharmacist to apply for
their Pharmacist Annual Retention. Please send to MPS the
1.     Fill in the Borang 10 from or
1 Borang 10 duly
2.     Print out your Statement of CPD Participation 2012 using
your login name and password at
2 Your statement of CPD
Your full name and address in the box at the bottom of this
3.     Purchase RM 50/- worth of Money Order,
Postal order or bank draft made payable to Ketua Setiausaha
Kementerian Kesihatan Malaysia
MPS will carry out steps 3 –
4.     Self-address envelope half A4
5.     Postage Stamp RM 1/- to be affixed to the
self-addressed envelope
6.     Registered Pos Barcode Label RM 2.20 (to be
provided and not to be stick on the envelope)
7.     Submit all the above (1-6) to the Pharmacy
Board in Petaling Jaya either by post or
Note: MPS only serves to carry out the logistics
of gathering all the paraphernalia (1-7) and forwarding them to the Pharmacy
Board.  It is the individual pharmacists who shall be responsible to fill in
accurately Borang 10 & send MPS your Statement of CPD Participation Year
2012.  Final approval and sending out the certificate is done by Pharmacy

Mode of Payment
A) r Cheque No ____________for RM
_________Payment payable
to “Malaysian Pharmaceutical Society”.
B) r By direct bank transfer for RM __________ via MAYBANK
ATM / Cash Deposit Machine / TT into MPS‘s account. Account Name: Malaysian
Pharmaceutical Society; Account Number: 0-14271-31967-2; Swift Code: MBBEMYKL;
Bank Name: Malayan Banking Berhad (Maybank) and Bank Address: 2, Lorong Rahim
Kajai 14, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia. You must send the
bank receipt to MPS to confirm your payment.
C) Credit Cards: r VISA   
r Master
Card   r
AMEX   For the sum of RM _________
Card number:
Valid till: ________________         Name­ on card:
___________________________                    Signature:


1. For MPS
RM 60/- (RM 50/- for your retention fees, RM 10/- for the
envelope, postage stamps, registered pos barcode label and bank charges)
2. For
Non-MPS members
(or lapsed members i.e. those who have not paid their
2012/2013 subscription)
RM 70/- (RM 50/- for your retention fees, RM 20/- for
envelope, postage stamps, registered pos barcode label, bank charges and
administrative charges).
3. Lapsed Annual Retention: You will
have to renew the 2012 Annual Retention first before you can renew your 2013
Annual Retention. The amount for this lapse retention (Year 2012) is RM 170/-
(RM 150/- for your lapsed retention fees, and RM 20/- for MPS bank, postage,
stationery and fax charges).

NOTE- This is a service to Members
(and Non-Members) of MPS. You can still submit your Annual Retention form direct
to the Lembaga Farmasi by yourself.


New Pharmacy Bill – Invitation for Public Comments


(extracted from the Pharmaceutical Services Division website)

Honourable Tun / Tan Sri / Dato ‘Sri / Datuk / Dato’ / Datin / ladies and

and Salam 1Malaysia,
I wish to take this opportunity to inform that the Pharmaceutical Services
Division, Ministry of Health Malaysia (PSD MOH) proposes the Pharmacy Bill to
replace the pre-independence legislations namely the Registration of Pharmacists
Act 1951, Poisons Act 1952, Sale of Drugs Act 1952, the Medicines (Advertisement
and Sale) Act 1956. At present, these legislations have become outdated to meet
the current challenges.
in the existing legislations have posed a major setback to PSD MOH in tackling
public complaints on the issue of counterfeited, adulterated and unregistered
medicinal product.
a view in safeguarding public interest, PSD MOH is proposing the Pharmacy Bill.
Therefore, PSD MOH would like to request feedback from the general public and
stakeholders including pharmaceutical and cosmetic industry, pharmaceutical
associations and higher education institutions.
behalf of the PSD MOH, I wish to extend my sincere gratitude for your
Director of Pharmaceutical Services

Ministry of Health Malaysia

>>Download attachment
(direct link to Pharmaceutical Services Division website)

>>Visit Ministry of
Health online public engagement site
and download (dateline 14th Dec 2012)

OR Online Public
Engagement on Pharmacy Bill
  / Rang Undang-Undang Untuk
Seranta Awam
(from MPS website)


Reference :


Dear Members

Following the report of the incidents of Enforcement
Officers confiscating Olivenol from some pharmacies, the MPS had asked for a
meeting with the Enforcement Officers to clarify the issue.

It was quite thankful that they are having a conference in Sabah and a prompt
meeting was convened with the MPS President.  What was derived from the meeting
was reported accurately to members. We have subsequently written a letter to the
Head of the National Pharmaceutical Control Bureau requesting for update of any
change of status.  The outcome of the meeting is already reported in last week

Since then new developments have taken place and indeed it is a pleasure to
update members that the affected products remain to be classify as food. 
Assurance was given that all seized products will be returned and no charges
will brought to the affected community pharmacy.

It has also been reported to us that the owner and distributor of Olivenol
had reached an agreement with the Enforcement Department that “Olivenol plus”
capsules classification status as food is legally valid and remains in force. 
Pharmacies who displayed and sold Olivenol did not commit any offence under the
Sales of Drug Act. Their continued sales of Olivenol is also legal and not in
violation of any law

Thank you and continue to Enjoy Pharmacy
Datuk Nancy Ho

4 December – Medicines Partnership of Australia – Consumers benefit from affordable medicines




Turnover Rent and Reporting Turnover to Landlords – Pharmacy Guidelines

Reference :



Workplace Relations Audit

Reference :


The Fair Work Ombudsman has notified the Guild that community pharmacies will
be audited for their compliance in workplace relations, mid-2013.

The Guild wants to help pharmacies prepare for this as it is very important
that the industry be of the highest standard in this field. The Guild is
offering an audit service to assist pharmacies get some ‘peace of mind’ before
the FWO audit takes place. After the voluntary Guild audit, pharmacies will feel
confident of a good result if the FWO chooses to check their records next

Click here to register

The completed registration forms will be directed to the each pharmacy’s
state branch. The branch will be in touch with the registrant to start the
confidential audit. Ultimately each pharmacy can receive advice and guidance as
to whether they are compliant or how to become compliant.

The Guild will charge an at-cost fee for the service.

The guild feels strongly that all pharmacies must comply with their
industrial obligations and are strongly encouraged to review their

For more information, assistance or advice, members can call the Workplace
Relations Manager in their State or Territory.


[Publication]: Forefront Volume 2 Number 45~48



Forefront is a regular e-newsletter from the Pharmacy Guild of

Subscription is free and – while content is produced with Guild members in
mind as the primary audience – open to anyone interested in news and current
events relating to community pharmacy in Australia.

Just as community pharmacists are at the forefront of primary health care in
the Australian community, Forefront aims to provide up-to-date,
relevant and valuable content to subscribers.

Subscribers will receive regular (typically weekly) email summaries that link
to more in-depth content on the Guild website.  These summaries aim to provide a
quick and convenient snapshot of news, which provides value to the reader even
if they do not have time to view the expanded content.

Click here to subscribe and see below for links to recent editions.

Forefront issues